Table 2

Mutually adjusted effects of neutrophil-to-lymphocyte ratio and body mass index and survival in 2,542 patients.

Patients
No.
Events
No.
Univariable model
HR (95% CI)
P valueMultivariable model 1a
HR (95% CI)
PMultivariable model 2b
HR (95% CI)
P
Overall survival
NLR< 0.001< 0.0010.004
 ≥36272791.497 (1.300–1.724)1.280 (1.111–1.475)1.236 (1.069–1.430)
 <31915639111
BMI (kg/m2)< 0.001< 0.001< 0.001
 <18.53491761.722 (1.461–2.030)1.607 (1.360–1.899)1.600 (1.350–1.897)
 ≥18.5 2193742111
NLR and BMI (kg/m2)c< 0.001< 0.001< 0.001
 Bothd98622.882 (2.213–3.752)2.469 (1.891–3.225)2.445 (1.853–3.225)
 Neithere1664525111
Recurrence-free survival
NLR< 0.001< 0.0010.008
 ≥36272461.447 (1.246–1.679)1.257 (1.082–1.460)1.230 (1.054–1.434)
 <31915584111
BMI (kg/m2)< 0.001< 0.001< 0.001
 <18.53491651.804 (1.521–2.140)1.672 (1.407–1.988)1.658 (1.389–1.979)
 ≥18.5 2193665111
NLR and BMI (kg/m2)c< 0.001< 0.001< 0.001
 Bothd98572.821 (2.142–3.715)2.404 (1.818–3.177)2.405 (1.802–3.209)
 Neithere1664476111

aAge, sex, adjuvant chemotherapy, and TNM stage were adjusted in multivariable model 1 for overall survival and recurrence-free survival; bAge, sex, adjuvant chemotherapy, primary tumor location, histopathological differentiation, number of lymph nodes dissected, TNM stage, family history of gastric cancer, Charlson comorbidity score, smoke, alcohol, anemia, hypoalbuminemia, type of gastrectomy and surgical complications were adjusted for a multivariable model 2 for overall survival and recurrence-free survival; cPatients were divided into 4 groups according to NLR and BMI: neither NLR ≥ 3 nor underweight (BMI < 18.5 kg/m2); NLR ≥ 3 only; underweight only; both NLR ≥ 3 and underweight; dIndicating NLR ≥ 3 and underweight (BMI < 18.5 kg/m2); eindicating NLR < 3 and BMI ≥ 18.5 kg/m2. NLR, neutrophil-to-lymphocyte ratio; BMI, body mass index; HR, hazard ratio; CI, confidence intervals; TNM, tumor-node-metastasis.